Biomedtracker

Report Library

2015 Chronic Lymphocytic Leukemia (CLL) Pulse

January 27, 2015

We performed a 5-question survey of 22 hematology-oncology specialists in the U.S. to gain insight on current prescribing practices for Chronic Lymphocytic Leukemia (CLL). Topics covered in this survey include:

Current usage of monoclonal antibodies and oral kinase inhibitors for CLL treatment
Comparison of expected future prescribing practices with predicted 2014 usage patterns from a December 2013 survey
Drugs covered include: Imbruvica (ibrutinib, PCYC/JNJ), Zydelig (idelalisib, GILD), venetoclax/ABT-199 (ABBV and Roche), Gazyva (obinutuzumab, Roche), and others

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

To purchase the CLL survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.

Indications Covered:

Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL

Additional Resources: